Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapport Therapeutics (RAPP) Operating Leases (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Operating Leases data on record, last reported at $8.2 million in Q1 2026.

  • On a quarterly basis, Operating Leases rose 19.81% to $8.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.2 million, a 19.81% increase, with the full-year FY2025 number at $8.7 million, up 1081.19% from a year prior.
  • Operating Leases reached $8.2 million in Q1 2026 per RAPP's latest filing, down from $8.7 million in the prior quarter.
  • Over the last five years, Operating Leases for RAPP hit a ceiling of $10.1 million in Q2 2025 and a floor of $739000.0 in Q4 2024.
  • A 4-year average of $5.3 million and a median of $6.8 million in 2025 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 49.93% in 2024, then skyrocketed 1081.19% in 2025.
  • Tracing RAPP's Operating Leases over 4 years: stood at $1.5 million in 2023, then crashed by 49.93% to $739000.0 in 2024, then surged by 1081.19% to $8.7 million in 2025, then fell by 6.2% to $8.2 million in 2026.
  • Business Quant data shows Operating Leases for RAPP at $8.2 million in Q1 2026, $8.7 million in Q4 2025, and $9.4 million in Q3 2025.